5 rebels killed, 2 India soldiers injured in Kashmir    Olympics: Tokyo Olympic organisers to secure 300 hotel rooms for athletes with COVID-19    Cairo Opera House to hold 27 concerts celebrating Ramadan    Austin makes first Israel visit by Biden official, Iran on the agenda    Iran reports electrical incident at Natanz nuclear site, no casualties    Egypt detects 801 new coronavirus infections; 43 deaths on Saturday    Bibliotheca Alexandrina launches hieroglyphics programme for primary school teachers    Egypt drafts new law prohibiting overseas transfer of historical documents    Egypt takes measures against German company for discrimination against Muslim Egyptian    Preview: Pyramids FC aim to avenge Raja loss in Confederation Cup    Carteron doesn't believe Esperance colluded with MC Alger to eliminate Zamalek    Arab League, Iraq discuss developments in country, region    1,300 Egyptian villages to install fibre-optic cables at cost of EGP 5.6bn    Egypt, Sudan reject Ethiopian proposal on data exchange ahead of second filling of GERD    Egypt, Tunisia agree on Libya support, cooperation on African topics    Novartis Egypt launches campaign to address critical risk of high blood cholesterol    Banks in Egypt increase capital to comply with new banking law    Finance Minister invites investors to benefit of Egypt's promising development opportunities    North Sinai's El-Arish Culture Palace reopens after a decade of closure    National Bank of Greece is officially ending its presence in Egypt    SMEs in emerging markets, including Egypt, need more fiscal: IMF    Ethiopia invites Egypt, Sudan to nominate operators in data exchange on GERD's 2nd filling    Indian states warn of COVID-19 vaccine shortages    Coronavirus vaccination does not invalidate Muslims' fasting: Egypt's religious endowments minister    Egypt re-elected as Vice-Chair of UN-Habitat Executive Board    Egypt welcomes resumption of US funding to UNRWA, Israel objects    Egypt, Uganda sign military intelligence-sharing agreement    Egyptian archaeological mission discovers 'Lost Golden City' in Luxor    Convicted terrorist with links to Islamic State group sentenced to life by Cairo court    INTERVIEW: JICA to invest up to $1 bln in Egypt through 2022: Regional director    Developing countries, including Egypt, will get 1.3 bln vaccine doses by 2021 end, IMF    PMI moves towards a smoke-free transformation, takes part in a webinar on e-cigarettes    IMF upgrades Egypt budget projections in its Fiscal Monitor Report    Cairo Photo Week aims to support Egyptian photography community: Marwa Abu Leila    Egypt's national youth fencing team achieves world glory    Karate Federation celebrates success of Egypt Cup    Zamalek's Shikabala nominated for best goal in CAF Champions League    Egypt's Court of Cassation acquits 41, sentences 9 to life in Sohag terrorism case    Egypt's President warns of grave consequences of water crises in Africa    Saudi Arabia approves opening of Banque Misr branch    Experiencing Egypt's grandeur    Don't miss Aziz Maraka's concerts in Cairo and Alexandria    Allianz Egypt partners with IGNITE to equip brand ambassadors for 2021 Olympics    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Egypt, Ethiopia, Sudan to resume Nile dam talks today    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Germany approves trials of COVID-19 vaccine candidate
Published in Ahram Online on 22 - 04 - 2020

Germany gave the green light for human trials of potential coronavirus vaccines developed by German biotech company BioNTech, which is racing teams in Germany, the U.S. and China to develop an agent that will stop the pandemic.
The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people, with more subjects, including some at higher risk from the disease, to be included in a second stage, German vaccines regulator the Paul Ehrlich Institut said on Wednesday.
BioNTech said it was developing four vaccine candidates under a programme named BNT162 with its partner, pharma giant Pfizer.
Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there.
BioNTech, which awarded the rights in China to BNT162 to Shanghai Fosun Pharmaceutical under a March collaboration deal, is competing with Germany's CureVac and U.S. biotech firm Moderna in the race to develop messenger-RNA vaccines.
These molecules act as recipes that instruct human cells to produce antigen proteins, which allow the immune system to develop an arsenal against future coronavirus infections.
Moderna started testing its experimental vaccine on humans in March.
Two different experimental coronavirus vaccines were approved for human tests by China last week. A unit of Sinovac Biotech and the Wuhan Institute of Biological Products are developing these compounds.
In March, China gave the green-light for another clinical trial for a vaccine candidate developed by the Academy of Military Medical Sciences and biotech firm CanSino Bio .


Clic here to read the story from its source.